Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, James A.R., Wilkinson, David, Holmes, Clive, Steart, Phil, Markham, Hannah, Weller, Roy O.·2003·Nature Medicine
DOI 10.1038/nm840

Cited by (1,000)

Items 601–700 of 1,000

  1. Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures
    John A. Lynch, Ana George, Patricia B. Eisenhauer, Kelly J. Conn, Wenwu Gao, Isabel Carreras, John M. Wells, Ann Carolyn McKee, M. David Ullman, Richard E. Fine · 2006 · Journal of Neuroscience Research
  2. Vaccination with Aβ-Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral Aβ and Lowers Plaque Burden in APP Transgenic Mice
    Patricia Bach, Jakob‐A. Tschäpe, Ferdinand Kopietz, Gundula Braun, Janina K. Baade, Karl‐Heinz Wiederhold, Matthias Staufenbiel, Marco Prinz, Thomas Deller, Ulrich Kalinke et al. · 2009 · The Journal of Immunology
  3. Prion Diseases: From Molecular Biology to Intervention Strategies
    Max Nunziante, Sabine Gilch, Hermann M. Schätzl · 2003 · ChemBioChem
  4. Novel Therapeutic Strategies in Alzheimer’s Disease: Pitfalls and Challenges of Anti-Amyloid Therapies and Beyond
    Giacomo Tondo, Fabiola De Marchi, Francesca Bonardi, Federico Menegon, Gaia Verrini, Davide Aprile, Matteo Anselmi, Letizia Mazzini, Cristoforo Comi · 2024 · Journal of Clinical Medicine
  5. Glial reactions and the clearance of amyloid β protein in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type
    Marion L. C. Maat–Schieman, Haruyasu Yamaguchi, Ingrid M. Hegeman-Kleinn, Corrie Welling‐Graafland, Remco Natté, Raymund A.C. Roos, Sjoerd G. van Duinen · 2004 · Acta Neuropathologica
  6. Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications
    Yannick Chantran, Jean Capron, Sonia Alamowitch, Pièrre Aucouturier · 2019 · Frontiers in Immunology
  7. Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?
    Rudy J. Castellani, Xiongwei Zhu, Hyoung‐gon Lee, Paula Isabel Moreira, George L. Perry, Mark A. Smith · 2007 · Expert Review of Neurotherapeutics
  8. Critical Issues for Successful Immunotherapy in Alzheimers Disease: Development of Biomarkers and Methods for Early Detection and Intervention
    Rawan M. Tarawneh, David M. Holtzman · 2009 · CNS & Neurological Disorders - Drug Targets
  9. Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
    Sandra Rocha · 2013 · Current Pharmaceutical Design
  10. NEUROLOGICAL INFECTION AND INFLAMMATION
    I Bone · 2004 · Journal of Neurology Neurosurgery & Psychiatry
  11. Pseudotumoral presentation of cerebral amyloid angiopathy–related inflammation
    Solène Ronsin, Gianluca Deiana, Ana Filipa Geraldo, Françoise Durand‐Dubief, Laure Thomas, Maïté Formaglio, Virginie Desestret, David Meyronet, Norbert Nighoghossian, Yves Berthezène et al. · 2016 · Neurology
  12. Antibody Responses, Amyloid-β Peptide Remnants and Clinical Effects of AN-1792 Immunization in Patients with AD in an Interrupted Trial
    Tyler A. Kokjohn, Alex E. Roher · 2009 · CNS & Neurological Disorders - Drug Targets
  13. Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?
    Jonathan K. Foster, Giuseppe Verdile, K A Bates, Ralph Nigel Martins · 2008 · Molecular Psychiatry
  14. Mechanisms of memory loss in Aβ and tau mouse models
    Ashe, K.H. · 2005 · Biochemical Society Transactions
  15. Vaccines for Alzheimer??s Disease
    Christopher Janus · 2003 · CNS Drugs
  16. Anti‐amyloid activity of neprilysin in plaque‐bearing mouse models of Alzheimer's disease
    M. Hasan Mohajeri, Katrin Kuehnle, Hong Li, Raphaël Poirier, Jay Tracy, Roger M. Nitsch · 2004 · FEBS Letters
  17. Untitled work
    2012 · PubMed
  18. Prevention approaches in a preclinical canine model of Alzheimer’s disease: benefits and challenges
    Paulina R. Davis, Elizabeth Head · 2014 · Frontiers in Pharmacology
  19. Potential Role of Venular Amyloid in Alzheimer’s Disease Pathogenesis
    Christopher Daniel Morrone, Jossana Bishay, JoAnne McLaurin · 2020 · International Journal of Molecular Sciences
  20. Therapeutic approaches for prion and Alzheimer's diseases
    Thomas Wısnıewskı, Einar M. Sigurdsson · 2007 · FEBS Journal
  21. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer’s disease
    Wang, Yan-Jiang, Gao, Chang-Yue, Yang, Miao, Liu, Xiao-Hong, Sun, Yin, Pollard, Anthony, Dong, Xiao-Yan, Wu, Xiao-Bing, Zhong, Jin-Hua, Zhou, Hua-Dong et al. · 2010 · Brain, Behavior, and Immunity
  22. Toward Alzheimer Therapies Based on Genetic Knowledge
    John Hardy · 2004 · Annual Review of Medicine
  23. Downregulated apoptosis and autophagy after anti‐Aβ immunotherapy in Alzheimer's disease
    Claire Paquet, James A. R. Nicoll, Seth Love, François Mouton‐Liger, Clive Holmes, Jacques Hugon, Delphine Boche · 2017 · Brain Pathology
  24. Invited Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials
    Delphine Boche, James A. R. Nicoll · 2020 · Neuropathology and Applied Neurobiology
  25. Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials
    Jacqui Nimmo, Louise Kelly, Ajay Kumar Verma, Roxana Octavia Carare, James A. R. Nicoll, Jean‐Cosme Dodart · 2021 · Frontiers in Neuroscience
  26. The use of a mutant TNF-α as a vaccine adjuvant for the induction of mucosal immune responses
    Hiroyuki Kayamuro, Yasuhiro Abe, Yasuo Yoshioka, Kazufumi Katayama, Tetsuya Nomura, Tokuyuki Yoshida, Kohei Yamashita, Tomoaki Yoshikawa, Yuichi Kawai, Tadanori Mayumi et al. · 2009 · Biomaterials
  27. Catalytic antibodies to amyloid β peptide in defense against Alzheimer disease
    Hiroaki Taguchi, Stephanie A. Planque, Yasuhiro Nishiyama, Paul Szabo, Marc E. Weksler, Robert Paul Friedland, Sudhir Paul · 2008 · Autoimmunity Reviews
  28. Amyloid at the blood vessel wall
    John Hardy, Karen M. Cullen · 2006 · Nature Medicine
  29. Abeta DNA Vaccination for Alzheimers Disease: Focus on Disease Prevention
    David H. Cribbs · 2010 · CNS & Neurological Disorders - Drug Targets
  30. Vaccination against Alzheimer disease
    Antonia Fettelschoss‐Gabriel, Franziska Zabel, Martin F. Bachmann · 2014 · Human Vaccines & Immunotherapeutics
  31. Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET
    Ing‐Tsung Hsiao, Chin‐Chang Huang, Chia‐Ju Hsieh, Shiaw‐Pyng Wey, Mei‐Ping Kung, Tzu‐Chen Yen, Kun‐Ju Lin · 2013 · European Journal of Nuclear Medicine and Molecular Imaging
  32. Immunotherapies in Alzheimer’s disease: Too much, too little, too late or off-target?
    Isabelle St‐Amour, Francesca Cicchetti, Frédéric Calon · 2015 · Acta Neuropathologica
  33. Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models
    Thomas Wısnıewskı, Allal Boutajangout · 2009 · Brain Structure and Function
  34. Identification of Novel Small Molecule Inhibitors of Amyloid Precursor Protein Synthesis as a Route to Lower Alzheimer’s Disease Amyloid-β Peptide
    Tada Utsuki, Qian-sheng Yu, Diane Davidson, De‐Mao Chen, Harold W. Holloway, Arnold R. Brossi, Kumar Sambamurti, Debomoy K. Lahiri, Nigel H. Greig, Tony Giordano · 2006 · Journal of Pharmacology and Experimental Therapeutics
  35. Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer’s disease: do we need new inhibitors?
    David Henry Small · 2005 · Expert Opinion on Emerging Drugs
  36. Inflammatory Cerebral Amyloid Angiopathy: A Broad Clinical Spectrum
    Aaron de Souza, Kate Tasker · 2023 · Journal of Clinical Neurology
  37. Investigating Interventions in Alzheimer's Disease with Computer Simulation Models
    Carole J. Proctor, Delphine Boche, Douglas A. Gray, James A. R. Nicoll · 2013 · PLoS ONE
  38. Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease
    Rakez Kayed · 2010 · Human Vaccines
  39. Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice
    Suhail Rasool, Ricardo Albay, Hilda Martínez‐Coria, Leonid Breydo, Jessica Wu, Saskia C. F. Milton, Sunit Misra, Andy T Tran, Anna Pensalfini, Frank M. LaFerla et al. · 2012 · Molecular Neurodegeneration
  40. Lessons from Anti-Amyloid-β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target
    Youmei Wang, Tao Yan, Honghui Lu, Weiming Yin, Bin Lin, Weibin Fan, Xiaoli Zhang, Pedro Fernández-Fúnez · 2017 · Neurodegenerative Diseases
  41. Insulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses
    Suélen Santos Alves, Rui Milton Patrício da Silva-Júnior, Gabriel Servilha‐Menezes, Jan Homolak, Melita Šalković‐Petrišić, Norberto Garcia‐Cairasco · 2021 · Journal of Alzheimer s Disease
  42. Advances on the Understanding of the Origins of Synaptic Pathology in AD
    Pascale N. Lacor · 2007 · Current Genomics
  43. Predicting Cerebral Amyloid Angiopathy-Related Intracerebral Hemorrhages and Other Cerebrovascular Disorders in Alzheimer’s Disease
    Masahito Yamada · 2012 · Frontiers in Neurology
  44. Virus-like particle based vaccines for Alzheimer disease
    Bryce Chackerian · 2010 · Human Vaccines
  45. Regression stage senile plaques in the natural course of Alzheimer’s disease
    T. Oide, T. Kinoshita, K. Arima · 2006 · Neuropathology and Applied Neurobiology
  46. HSV amplicon-mediated Aβ vaccination in Tg2576 mice: differential antigen-specific immune responses
    William J. Bowers, Michael A. Mastrangelo, Hilary A. Stanley, Ann E. Casey, Lawrence J. Milo, Howard J. Federoff · 2004 · Neurobiology of Aging
  47. Lifelong Management of Amyloid-Beta Metabolism to Prevent Alzheimer's Disease
    Sam Gandy · 2012 · New England Journal of Medicine
  48. Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds
    Nelly Joseph‐Mathurin, Olène Dorieux, Stéphanie G. Trouche, Allal Boutajangout, Audrey Kraska, Pascaline Fontès, Jean‐Michel Verdier, Einar M. Sigurdsson, Nadine Mestre‐Francés, Marc Dhénain · 2013 · Neurobiology of Aging
  49. A third-generation mouse model of Alzheimer's disease shows early and increased cored plaque pathology composed of wild-type human amyloid β peptide
    Kaori Sato, Naoto Watamura, Ryo Fujioka, Naomi Mihira, Misaki Sekiguchi, Kenichi Nagata, Toshio Ohshima, Takashi Saito, Takaomi C. Saido, Hiroki Sasaguri · 2021 · Journal of Biological Chemistry
  50. Anti-Amyloid-β Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model
    Jinghong Kou, Hong-Duck Kim, Abhinandan Pattanayak, Min Song, Jeong-Eun Lim, Hiroaki Taguchi, Sudhir Paul, John R. Cirrito, Selvarangan Ponnazhagan, Ken-ichiro Fukuchi · 2011 · Journal of Alzheimer s Disease
  51. Is passive immunization for Alzheimer's disease ‘alive and well’ or ‘dead and buried’?
    Gregory A. Jicha · 2009 · Expert Opinion on Biological Therapy
  52. Stromal cell-derived factor 1α decreases β-amyloid deposition in Alzheimer's disease mouse model
    Qi Wang, Yi Xu, Jincao Chen, Yuanyuan Qin, Mao Liu, Yang Liu, Min-Jie Xie, Zhiyuan Yu, Zhou Zhu, Wei Wang · 2012 · Brain Research
  53. Determination of Spatial and Temporal Distribution of Microglia by 230nm-High-Resolution, High-Throughput Automated Analysis Reveals Different Amyloid Plaque Populations in an APP/PS1 Mouse Model of Alzheimers Disease
    Katja Scheffler, Jan Stenzel, Markus Krohn, Cathleen Lange, Jacqueline Hofrichter, Toni Schumacher, Thomas Brüning, Anne-Sophie Plath, Lary C. Walker, Jens Pahnke · 2011 · Current Alzheimer Research
  54. Mannan-Abeta28conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice
    Irina Petrushina, Anahit Ghochikyan, Mikayel Mkrtichyan, Grigor Mamikonyan, Nina Movsesyan, Rodmehr Ajdari, Vitaly Vasilevko, Adrine Karapetyan, Andrew Lees, Michael G. Agadjanyan et al. · 2008 · Journal of Neuroinflammation
  55. The β‐amyloid peptide of Alzheimer's disease decreases adhesion of vascular smooth muscle cells to the basement membrane
    Su San Mok, Dušan Lošić, Colin James Barrow, Bradley J. Turner, Colin Louis Masters, Lisandra L. Martin, David Henry Small · 2005 · Journal of Neurochemistry
  56. Novel approaches for immunotherapeutic intervention in Alzheimer's disease
    Vitaly Vasilevko, David H. Cribbs · 2006 · Neurochemistry International
  57. Efficacy of anti-Aβ antibody isotypes used for intracerebroventricular immunization in TgCRND8
    Neelima B. Chauhan, George J. Siegel · 2005 · Neuroscience Letters
  58. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Aβ1–15 reduces Aβ burden and behavioral impairment without Aβ-specific T cell response
    Juntao Zou, Zhibin Yao, Ge Zhang, Huaqiao Wang, Jie Xu, David T. Yew, E. Lucy Forster · 2008 · Journal of the Neurological Sciences
  59. Attenuation of Aβ deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking
    JENNIFER A. COURT, M. Johnson, Dorota Religa, Jessica Keverne, Raj N. Kalaria, Evelyn Jaros, Ian Grant McKeith, Robert Perry, Jan Näslund, Elaine King Perry · 2005 · Neuropathology and Applied Neurobiology
  60. Dementia Update 2003
    John C. Morris · 2003 · Alzheimer Disease & Associated Disorders
  61. Rapid induction of autoantibodies against Nogo‐A and MOG in the absence of an encephalitogenic T cell response: implication for immunotherapeutic approaches in neurological diseases
    Doron Merkler, Thomas Oertle, Armin Buss, Daniel D. Pinschewer, Lisa Schnell, Florence M. Bareyre, Martin Kerschensteiner, Bigna S. Buddeberg, Martin E. Schwab · 2003 · The FASEB Journal
  62. Future directions in the treatment of Alzheimer?s disease
    Roger Alan Bullock · 2004 · Expert Opinion on Investigational Drugs
  63. Complex regulation of acute and chronic neuroinflammatory responses in mouse models deficient for nuclear factor kappa B p50 subunit
    Taisia Rõlova, Lakshman Puli, Johanna M. Magga, Hiramani Dhungana, Katja M. Kanninen, Sara Wojciehowski, Antero Salminen, Heikki Tanila, Jari Koıstınaho, Tarja Malm · 2013 · Neurobiology of Disease
  64. Inhibiting β-Secretase Activity in Alzheimer's Disease Cell Models with Single-Chain Antibodies Specifically Targeting APP
    Shanta P. Boddapati, Yona Levites, Michael R. Sierks · 2010 · Journal of Molecular Biology
  65. Beta-Amyloid Peptides Enhance the Proliferative Response of Activated CD4+CD28+ Lymphocytes from Alzheimer Disease Patients and from Healthy Elderly
    Agnieszka Jóźwik, Jerzy Landowski, Leszek Bidzan, Tamàs Fülöp, Ewa Bryl, Jacek Maciej Witkowski · 2012 · PLoS ONE
  66. Piceatannol, a natural analogue of resveratrol, effectively reduces beta-amyloid levels via activation of alpha-secretase and matrix metalloproteinase-9
    Boyoung Choi, Suyeon Kim, Bong-Geum Jang, Min-Ju Kim · 2016 · Journal of Functional Foods
  67. Generation of Transgenic Cynomolgus Monkeys Overexpressing the Gene for Amyloid-β Precursor Protein
    Yasunari Seita, Toshifumi Morimura, Naoki Watanabe, Chizuru Iwatani, Hideaki Tsuchiya, Shinichiro Nakamura, Toshiharu Suzuki, Daijiro Yanagisawa, Tomoyuki Tsukiyama, Masataka Nakaya et al. · 2020 · Journal of Alzheimer s Disease
  68. PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) ameliorate learning and memory deficit in a rat model of Alzheimer’s disease: Potential participation of STIMs
    Mehdi Sanati, Samaneh Aminyavari, Fariba Khodagholi, Mohammad Javad Hajipour, Payam Sadeghi, Marzieh Noruzi, Aynaz Moshtagh, Homayoon Behmadi, Mohammad Sharif Sharifzadeh · 2021 · NeuroToxicology
  69. A History of Senile Plaques: From Alzheimer to Amyloid Imaging
    Thomas G. Beach · 2022 · Journal of Neuropathology & Experimental Neurology
  70. Microglial autophagy in Alzheimer’s disease and Parkinson’s disease
    Wang, Zhifu, Wang, Qi, Li, Shihua, Li, Xiao-Jiang, Yang, Weili, He, Dajian · 2023 · Frontiers in Aging Neuroscience
  71. Systemic and Central Immunity in Alzheimer's Disease: Therapeutic Implications
    Joe Butchart, Clive Holmes · 2011 · CNS Neuroscience & Therapeutics
  72. Amyloid beta peptide immunotherapy in Alzheimer disease
    Julien Delrieu, Pierre‐Jean Ousset, T. Voisin, Bruno J. Vellas · 2014 · Revue Neurologique
  73. The endocannabinoid system in neuropathological states
    José Antonio Martínez-Orgado, Javier Fernández‐Ruíz, Julián Romero · 2009 · International Review of Psychiatry
  74. A Simulation Model of Periarterial Clearance of Amyloid-β from the Brain
    Alexandra K. Diem, Mingyi Tan, Neil W. Bressloff, Cheryl A. Hawkes, Alan W. J. Morris, Roy O. Weller, Roxana Octavia Carare · 2016 · Frontiers in Aging Neuroscience
  75. Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case–control study
    Baayla D.C. Boon, Yoav D. Piura, Christina M. Moloney, Jessica L Chalk, Sarah Lincoln, Matthew H. Rutledge, Darren M. Rothberg, Naomi Kouri, Kelly M. Hinkle, Shanu Faerch Roemer et al. · 2025 · The Lancet Neurology
  76. Treatment‐related amyloid clearance (TRAC): a framework to characterize patients in the era of anti‐amyloid therapies
    Renaud La Joie, Jeffrey L. Cummings, Jeffrey L. Dage, Douglas R Galasko, Miloš D. Ikonomović, Thomas K. Karikari, Susan M. Landau, Jorge J. Llibre‐Guerra, Catherine Jane Mummery, Rik Ossenkoppele et al. · 2025 · Alzheimer s & Dementia
  77. Molecular Approaches to the Treatment, Prophylaxis, and Diagnosis of Alzheimer’s Disease: Tangle Formation, Amyloid-β, and Microglia in Alzheimer’s Disease
    Kazuyuki Takata, Yoshihisa Kitamura · 2012 · Journal of Pharmacological Sciences
  78. Immunization targeting a minor plaque constituent clears β-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model
    José Morales‐Corraliza, Stephen D. Schmidt, Matthew J. Mazzella, Jason D. Berger, Donald A. Wilson, Daniel W. Wesson, Mathias Jucker, Efrat Levy, Ralph A. Nixon, Paul M. Mathews · 2012 · Neurobiology of Aging
  79. Dysregulated Metabolism of the Amyloid‐β Protein and Therapeutic Approaches in Alzheimer Disease
    Kazunori Kikuchi, Kiwami Kidana, Takuya Tatebe, Taisuke Tomita · 2017 · Journal of Cellular Biochemistry
  80. Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis
    Jatin Machhi, Pravin Yeapuri, Milica Marković, Milankumar Patel, Wenhui Yan, Yaman Lu, Jacob D. Cohen, Mahmudul Hasan, Mai Mohamed Abdelmoaty, You Zhou et al. · 2022 · ACS Chemical Neuroscience
  81. Bapineuzumab Alters Aβ Composition: Implications for the Amyloid Cascade Hypothesis and Anti-Amyloid Immunotherapy
    Alex E. Roher, David H. Cribbs, Ronald C. Kim, Chera L. Maarouf, Charisse M. Whiteside, Tyler A. Kokjohn, Ian D. Daugs, Elizabeth Head, Carolyn Liebsack, Geidy E. Serrano et al. · 2013 · PLoS ONE
  82. Anti‐Aβ: The good, the bad, and the unforeseen
    Oleg Broytman, James S. Malter · 2003 · Journal of Neuroscience Research
  83. AAV-mediated neuronal expression of an scFv antibody selective for Aβ oligomers protects synapses and rescues memory in Alzheimer models
    María Clara Sellés, Juliana T.S. Fortuna, Magalí Cecilia Cercato, Luís E. Santos, Luciana Domett, Andre L.B. Bitencourt, Mariane Favero Carraro, Amanda Santos de Souza, Helena Janíčková, Caroline Vieira Azevedo et al. · 2022 · Molecular Therapy
  84. DNA epitope vaccine containing complement component C3d enhances anti-amyloid-β antibody production and polarizes the immune response towards a Th2 phenotype
    Nina Movsesyan, Mikayel Mkrtichyan, Irina Petrushina, Ted M. Ross, David H. Cribbs, Michael G. Agadjanyan, Anahit Ghochikyan · 2008 · Journal of Neuroimmunology
  85. 39-Week Toxicity and Toxicokinetic Study of Ponezumab (PF-04360365) in Cynomolgus Monkeys with 12-Week Recovery Period
    Gary B. Freeman, John Chia-Yang Lin, Jaume Pons, Nancy Raha · 2012 · Journal of Alzheimer s Disease
  86. Why therapies for Alzheimer’s disease do not work: Do we have consensus over the path to follow?
    Zareen Amtul · 2015 · Ageing Research Reviews
  87. Novel Therapeutic Modalities to Address Nondrugable Protein Interaction Targets
    Errol B. De Souza, Sharon T. Cload, P. Shannon Pendergrast, Dinah W.Y. Sah · 2008 · Neuropsychopharmacology
  88. Clinical trials of prion disease therapeutics
    Gianluigi Forloni, Ignazio Roiter, Fabrizio Tagliavini · 2019 · Current Opinion in Pharmacology
  89. Identification of two immunogenic domains of the prion protein—PrP—which activate class II-restricted T cells and elicit antibody responses against the native molecule
    Sylvie Grégoire, Caroline Logre, Pat Metharom, Estelle Loing, Jacques Chomilier, M. Bruley-Rosset, Pièrre Aucouturier, Claude Carnaud · 2004 · Journal of Leukocyte Biology
  90. Vessel ultrastructure in APP23 transgenic mice after passive anti-Aβ immunotherapy and subsequent intracerebral hemorrhage
    Guido J. Burbach, Andreas Vlachos, Estifanos Ghebremedhin, Domenico Del Turco, Janaky Coomaraswamy, Matthias Staufenbiel, Mathias Jucker, Thomas Deller · 2006 · Neurobiology of Aging
  91. Novel Aβ peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease
    Jun Zhou, Maria I Fonseca, Rakez Kayed, Irma Hernandez, Scott D. Webster, Ozkan Yazan, David H. Cribbs, Charles G. Glabe, Andrea J. Tenner · 2005 · Journal of Neuroinflammation
  92. Proteolytic Antibody Light Chains Alter β-Amyloid Aggregation and Prevent Cytotoxicity
    Ruitian Liu, Chad McAllister, Yuri L. Lyubchenko, Michael R. Sierks · 2004 · Biochemistry
  93. Immunotherapy as treatment for Alzheimer’s disease
    Cheryl A. Hawkes, JoAnne McLaurin · 2007 · Expert Review of Neurotherapeutics
  94. Amyloid cascade hypothesis
    Deng-Shun Wang, Dennis W. Dickson, James S. Malter · 2011 · Figshare
  95. Immunization against angiotensins for the treatment of hypertension
    Patrik Maurer, Martin F. Bachmann · 2009 · Clinical Immunology
  96. Amyloids: The History of Toxicity and Functionality
    Elmira I. Yakupova, Liya G. Bobyleva, Sergey A. Shumeyko, Ivan M. Vikhlyantsev, A. G. Bobylev · 2021 · Biology
  97. Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut
    Jacqui Nimmo, Harry Smith, Chang Yi Wang, Jessica L. Teeling, James A. R. Nicoll, Ajay Kumar Verma, Jean‐Cosme Dodart, Zhi Liu, Lin Feng, Roxana Octavia Carare · 2021 · Acta Neuropathologica
  98. Cessation of Neoangiogenesis in Alzheimer's Disease Follows Amyloid-beta Immunization
    Kaan E. Biron, Dara L. Dickstein, Rayshad Gopaul, Franz Fenninger, Wilfred Arthur Jefferies · 2013 · Scientific Reports
  99. Detection of amyloid β protein in the urine of Alzheimer's disease patients and healthy individuals
    Manabu Takata, Manabu Nakashima, Taro Takehara, Hideyo Baba, Kazuyuki Machida, Yoshiharu Akitake, Kazuhiko Ono, Masato Hosokawa, Mitsuo Takahashi · 2008 · Neuroscience Letters
  100. Plasma antibodies to Aβ40 and Aβ42 in patients with Alzheimer's disease and normal controls
    Wuhua Xu, Takeshi Kawarabayashi, Etsuro Matsubara, Kentaro Deguchi, Tetsuro Murakami, Yasuo Harigaya, Masaki Ikeda, Masakuni Amari, Ryozo Kuwano, Koji Abe et al. · 2008 · Brain Research